Last Update 11 Jun 26

TXG: Multiomic Expansion And Spatial Launch Plans Will Shape Fairly Valued Outlook

Analysts have lifted their price targets on 10x Genomics by a range of $2 to $10, reflecting updated views on the stock. These revisions are now feeding into this valuation narrative and refined assumptions around discount rate, revenue growth, profit margins, and future P/E.

Analyst Commentary

Recent Street research around 10x Genomics has leaned toward more constructive views, with several bullish analysts revisiting their models and adjusting assumptions around discount rates, revenue trajectories, margins, and future P/E multiples. These moves are showing up most clearly in a series of upward price target revisions and at least one ratings upgrade.

Across the research, the focus is on how execution against the current roadmap could support the stock's valuation framework, rather than on any single short term data point. For readers, the cluster of positive actions in a relatively tight time frame signals that analysts are recalibrating their risk and reward expectations around the story.

Bullish Takeaways

Multiple bullish analysts have raised price targets, including increases of US$2, US$3, US$6, US$8, US$9, and US$10. Collectively, these changes point to a more optimistic view of upside potential relative to prior assumptions.
The presence of a price target lift from a major firm such as JPMorgan adds visibility to the positive sentiment, as larger houses often influence how other institutions frame the valuation debate.
An upgrade from William Blair sits alongside those target changes. This suggests not only a shift in modeled fair value but also a reassessment of execution risk and the stock's risk reward profile.
Taken together, the higher targets and the upgrade indicate that bullish analysts see room for 10x Genomics to better align its trading level with their assumptions on future revenue, profitability, and P/E multiples, provided the company delivers on its current plans.

What’s in the News

10x Genomics acquired Proteintech Genomics, adding the Human Discovery Panel, which is described as the largest antibody based single cell protein panel compatible with 10x Flex chemistry, expanding its single cell proteomics and multiomic offering. Source: Proteintech Genomics acquisition announcement.
The company highlighted that integrating Proteintech Genomics’ proteomic tools with its existing transcriptomic platforms is intended to support combined RNA and protein analysis for single cell and spatial biology research. Source: Proteintech Genomics acquisition announcement.
10x Genomics announced Atera, an in situ spatial biology platform positioned for whole transcriptome spatial analysis with single cell sensitivity across fresh frozen and FFPE tissue, with commercial launch tied to the AACR Annual Meeting 2026 and pre orders already open. Source: Company product announcement on Atera.
Early Atera data are being featured in scientific settings, including Carl June’s Opening Plenary session and posters at the AACR Annual Meeting 2026, with examples of colorectal and other tumor samples being mapped at single cell resolution. Source: AACR 2026 conference materials.
10x Genomics is pairing Atera with a new cloud analysis platform and Catalyst Research Services, giving researchers options to store and analyze spatial datasets in the cloud or on premise and to submit samples directly for whole transcriptome spatial work. Source: Company product announcement on Atera and 10x Cloud.

Valuation Changes

Fair Value: Model fair value remains at $32.0. The updated work does not change the central price anchor in the framework.
Discount Rate: The discount rate has risen slightly from 7.71% to 7.78%, which modestly raises the hurdle applied to projected cash flows.
Revenue Growth: The revenue growth assumption has risen slightly from 8.54% to 8.63%, reflecting a small adjustment in the top line outlook used in the model.
Net Profit Margin: The net profit margin assumption is essentially unchanged, moving slightly from 15.58% to 15.57%, so profitability expectations are broadly stable.
Future P/E: The future P/E multiple has risen marginally from 42.10x to 42.12x, indicating only a very small tweak to the valuation multiple applied to future earnings.

1 view

Key Takeaways

Accelerating adoption of innovative products and new data-driven applications is driving faster-than-expected revenue growth and expanding high-margin software and consumables streams.
Expansion in biopharma, global research, and new regulatory-backed markets are enabling rapid, diversified growth and improved long-term earnings stability.
Revenue instability, rising competition, reduced research funding, and shrinking market opportunities threaten growth, profitability, and 10x Genomics' ability to sustain innovation leadership.

Catalysts

About 10x Genomics

A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.What are the underlying business or industry changes driving this perspective?

Analyst consensus sees lower-priced products like GEM-X Flex and on-chip multiplexing sparking gradual volume growth, but this likely understates demand elasticity-recent evidence points to strong, accelerating reaction volume growth, suggesting a much faster inflection that could drive a step change in consumables revenue and overall top-line performance.
While analysts broadly expect biopharma to become a larger contributor to revenue over time, the combination of a dedicated biopharma sales force, new use cases in AI-enabled drug discovery, and accelerating interest in spatial biology positions 10x Genomics to capture this market far quicker than expected, potentially more than doubling biopharma-driven revenues and significantly expanding long-term operating margins.
The rapid adoption of 10x platforms in global consortia and multi-country initiatives, alongside resilient APAC demand-even in the face of US academic funding headwinds-suggests substantial untapped international revenue upside as genomics research funding and infrastructure expand globally, improving both revenue diversification and stability.
Integration of advanced cloud-based informatics, large-scale data analytics, and multiomic capabilities with 10x's instruments is catalyzing entirely new application domains-especially in precision medicine and AI-driven clinical research-unlocking high-value workflows and recurring high-margin software and consumables revenue, boosting both top-line and gross margins.
The industry-wide shift away from animal testing, with regulatory backing by the FDA and broader adoption of organoid models, is creating a fast-growing, high-value end market where single-cell and spatial platforms like Chromium and Xenium are fundamental, driving durable, multi-year instrument placements and consumables pull-through that support earnings growth and predictability.

10x Genomics Earnings and Revenue Growth

10x Genomics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more optimistic perspective on 10x Genomics compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
The bullish analysts are assuming 10x Genomics's revenue will grow by 8.6% annually over the next 3 years.
The bullish analysts are not forecasting that 10x Genomics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate 10x Genomics's profit margin will increase from -3.5% to the average US Life Sciences industry of 15.6% in 3 years.
If 10x Genomics's profit margin were to converge on the industry average, you could expect earnings to reach $127.5 million (and earnings per share of $0.95) by about June 2029, up from -$22.7 million today.
In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 42.3x on those 2029 earnings, up from -163.1x today. This future PE is greater than the current PE for the US Life Sciences industry at 40.0x.
The bullish analysts expect the number of shares outstanding to grow by 1.98% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.78%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Sharp reductions and ongoing uncertainty in US academic and government research funding-a base which accounts for 40 to 50 percent of 10x Genomics' revenue-create unpredictable customer purchasing behavior, making annual revenue projections unreliable and translating into substantial near
and long-term risk to revenue growth and earnings.
Intensifying competition from both established players and innovative startups, coupled with recent large declines (such as a 42 percent year-over-year drop in instrument revenue) despite strong product launches, signal market share erosion and could result in compressed gross margins and weakening profitability.
Significant and sustained decreases in capital expenditure for research instrumentation, amid challenging macroeconomic conditions and constrained budgets worldwide, have already led to reduced instrument sales and threaten to further limit top-line growth and operating income.
High research and development spending relative to revenue, in an environment where both R&D and headcount are now being cut, raises concerns that maintaining technology leadership will increasingly strain net margins or impair future innovation and competitiveness if cost-cutting continues.
Market saturation in developed countries and shifting funding priorities-potentially away from genomics to other fields like proteomics or digital health-could dampen long-term demand for 10x Genomics' products, narrowing the company's addressable market and constraining revenue expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bullish price target for 10x Genomics is $32.0, which represents up to two standard deviations above the consensus price target of $25.77. This valuation is based on what can be assumed as the expectations of 10x Genomics's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $32.0, and the most bearish reporting a price target of just $20.0.
In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $818.9 million, earnings will come to $127.5 million, and it would be trading on a PE ratio of 42.3x, assuming you use a discount rate of 7.8%.
Given the current share price of $29.11, the analyst price target of $32.0 is 9.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on 10x Genomics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Advanced Genomics Trends Will Unlock Precision Medicine